Associations of \textit{ABCB1}, \textit{NFKB1}, \textit{CYP3A}, and \textit{NR1I2} polymorphisms with cyclosporine trough concentrations in Chinese renal transplant recipients

Yu ZHANG$^{1, \#}$, Jia-li Li$^{1, \#}$, Qian FU$^2$, Xue-ding WANG$^3$, Long-shan LIU$^2$, Chang-xi WANG$^{2, \ast}$, Wen XIE$^3$, Zhuo-jia CHEN$^1$, Wen-ying SHU$^1$, Min HUANG$^1$, \ast

$^1$Institute of Clinical Pharmacology, School of Pharmaceutical Sciences, Sun Yat-sen University, Guangzhou 510006, China; $^2$Kidney Transplant Department, Transplant Center, the First Affiliated Hospital of Sun Yat-sen University, Guangzhou 510080, China; $^3$Center for Pharmacogenetics and Department of Pharmaceutical Sciences, University of Pittsburgh, Pittsburgh, PA 15261, USA

**Aim:** Cyclosporine requires close therapeutic drug monitoring because of its narrow therapeutic index and marked inter-individual pharmacokinetic variation. In this study, we investigated the associations of \textit{CYP3A4}, \textit{CYP3A5}, \textit{ABCB1}, \textit{NFKB1}, and \textit{NR1I2} polymorphisms with cyclosporine concentrations in Chinese renal transplant recipients in the early period after renal transplantation.

**Methods:** A total of 101 renal transplant recipients receiving cyclosporine were genotyped for \textit{CYP3A4*1G}, \textit{CYP3A5*3}, \textit{ABCB1 C1236T}, \textit{G2677T/A}, \textit{C3435T}, \textit{NFKB1 -94 ins/del ATTG}, and \textit{NR1I2} polymorphisms. Cyclosporine whole blood levels were measured by a fluorescence polarization immunoassay. Trough concentrations of cyclosporine were determined for days 7-18 following transplantation.

**Results:** The dose-adjusted trough concentration ($C_0$) of cyclosporine in \textit{ABCB1} 2677 TT carriers was significantly higher than that in GG carriers together with GT carriers [90.4±24.5 vs 67.8±26.8 (ng/mL)/(mg/kg), $P=0.001$]. \textit{ABCB1} 3435 TT carriers had a significantly higher dose-adjusted $C_0$ of cyclosporine than CC carriers together with CT carriers [92.0±24.0 vs 68.4±26.5 (ng/mL)/(mg/kg), $P=0.002$]. Carriers of the \textit{ABCB1} 1236TT-2677TT-3435TT haplotype had a considerably higher CsA $C_0/D$ than carriers of other genotypes [97.2±32.9 vs 55.1±15.1 (ng/mL)/(mg/kg), $P=0.026$]. Among non-carriers of the \textit{ABCB1} 2677 TT and 3435 TT genotypes, patients with the \textit{NFKB1} -94 ATTG ins/ins genotype had a significantly higher dose-adjusted $C_0$ than those with the -94 ATTG del/del genotype [75.9±32.9 vs 55.1±15.1 (ng/mL)/(mg/kg), $P=0.026$].

**Conclusion:** These results illustrate that the \textit{ABCB1} and \textit{NFKB1} genotypes are closely correlated with cyclosporine trough concentrations, suggesting that these SNPs are useful for determining the appropriate dose of cyclosporine.

**Keywords:** cyclosporine; \textit{ABCB1}; \textit{NFKB1}; \textit{NR1I2}; \textit{CYP3A}; genetic polymorphism

**Acta Pharmacologica Sinica** (2013) 34: 555–560; doi: 10.1038/aps.2012.200; published online 18 Mar 2013

**Introduction**

As a member of the calcineurin inhibitor (CNI) family, cyclosporine (CsA) is a first-line immunosuppressant widely used to prevent allograft rejection after solid organ transplantation. However, the bioavailability of cyclosporine ranges from less than 5% to 89% in transplant patients$^{[1]}$. Owing to its narrow therapeutic index and marked inter-individual pharmacokinetic variation, therapeutic drug monitoring (TDM) is necessary to adjust the dosage and reduce toxicity$^{[2]}$. Nevertheless, TDM is hysteretic for optimizing efficacy and limiting toxicity of cyclosporine. Therefore, identifying factors that affect the pharmacokinetics of cyclosporine has great potential for improving the safety and efficacy profile.

Cyclosporine is a substrate of cytochrome 3A4 and 3A5 (\textit{CYP3A4} and \textit{CYP3A5}) and P-glycoprotein (P-gp/MDR1, encoded by \textit{ABCB1}). Most previous studies have focused on the influence of genetic variants in the genes encoding \textit{CYP3A4}, \textit{CYP3A5}, and P-gp on CsA pharmacokinetics but have yielded conflicting results$^{[3]}$. In addition to the differences in study populations, particularly in sample size and ethnicities, there might be other, as-yet undiscovered, genetic factors that influence the expression or function of \textit{CYP3A4}, \textit{CYP3A5} or P-gp to be discovered.

The pregnane X receptor (PXR, encoded by \textit{NR1I2}) is
reported to be the key nuclear receptor regulating the expression of CYP3A4, CYP3A5, and ABCB1[4]. Factors affecting the expression or function of PXR, such as single nucleotide polymorphisms (SNPs), may influence the expression of downstream target genes. T25385C, G24113A, C6994T, C4356T, and G7635A have been reported to be associated with CYP3A4 phenotype, activity, and content, whereas A11156C has been associated with variable P-gp levels[5-7]. A24622T and C24446A in exon1 have been found to be associated with PXR levels in previous studies from our laboratory[8], suggesting that these two SNPs may also be correlated with the expression of CYP3A4, CYP3A5, or ABCB1.

NF-κB, a protein complex found in almost all animal cell types, is a transcription factor critical for inflammatory responses. It has long been observed that inflammatory responses and infections decrease drug metabolism capacity in humans[5, 10]. The possible effects of NF-κB on enzymes and transporters related to drug metabolism have been studied because NF-κB is a key regulator of inflammation. Gu et al revealed that NF-κB competitively binds to the retinoid X receptor (RXR), thus preventing the PXR-RXR complex from binding to consensus DNA sequences in the regulatory regions of downstream genes, including CYP3A4 and ABCB1[11]. The NFKB1 gene encodes the p50 subunit of NF-κB, which com-

The aim of this study was to comprehensively evaluate the influence of SNPs in CYP3A4, CYP3A5, ABCB1, NR1I2, and NFKB1 on cyclosporine concentration in a group of Chinese renal transplant recipients during the early stage after transplantation.

DNA extraction and genotyping
Total genomic DNA was extracted from peripheral leukocytes according to a previously described method[14]. CYP3A5*3 (A6986G), CYP3A4*1G (G20230A), ABCB1 C1236T, G2677T/A, and C3435T polymorphisms were detected by using previously reported polymerase chain reaction restriction-fragment length polymorphism (PCR-RFLP) methods[15-17]. The NFKB1 -94ins/del ATTG polymorphism was detected by TaqMan® SNP Genotyping Assay. Polymorphisms of NR1I2, including T25385C, A24622T, C24446A, G24113A, C4356T, A601G, G7635A, A11156C, and C6994T, were genotyped by direct sequencing[5-8].

Statistical analysis
The pair-wise linkage disequilibrium (LD) for SNPs was estimated by SHEsis (http://analysis2.bio-x.cn/myAnalysis.php). ABCB1 1236-2677-3435 haplotype analysis was performed by PHASE 2.1. Groups were compared using nonparametric tests. For the analysis of continuous pharmacologic variables, we used patient genotypes as categorical independent variables. The Hardy-Weinberg equilibrium test was performed using an appropriate χ² test. The Mann-Whitney U test was used for comparisons between two groups, and the Kruskal-Wallis H test was used for comparisons among several groups.
Statistical analysis was performed using SPSS version 17.0 for Windows (SPSS Inc, Chicago, IL, USA). The results are expressed as the mean±standard deviation (SD). A P-value less than 0.05 was considered statistically significant.

**Results**

**Genotypes frequencies**

A total of 101 renal transplant recipients were genotyped for polymorphisms in *CYP3A5*, *CYP3A4*, *ABCB1*, *NFKB1*, and *NR1I2*. All mutant allele and genotype frequencies were in agreement with previous reports in Han Chinese populations. No differences were observed between allograft recipients and the healthy population, and no deviations from the Hardy-Weinberg equilibrium were observed.

*CYP3A4*1G was in moderate linkage disequilibrium (LD) with *CYP3A5*3 (D’=0.63). A moderately high degree of LD between *ABCB1* C1236T, G2677T/A, and C3435T was also observed. For C1236T-G2677T/A, G2677T/A-C3435T, and C3435T-C1236T, D’ was 0.56, 0.79 and 0.72, respectively, which agreed with previous reports. *NFKB1* T25385C and G24113A were in complete linkage disequilibrium (D’=1), whereas *NFKB1* C4356T was strongly linked to A-601G SNP (D’=0.785). No significant linkage was found between other individual combinations of SNPs.

According to the haplotype analysis, the frequencies of the three major haplotypes (1236-2677-3435) of *ABCB1* were 32.3% for TTT, 25.7% for TGC and 20.4% for CGC. The remaining haplotypes constituted 21.6% of the patients’ haplotypes.

**Association between *ABCB1* genotype and CsA dose-adjusted trough blood concentrations**

A significantly higher CsA C_0/D was observed in *ABCB1* 2677 TT carriers than in the other 2677 genotype carriers [90.4±24.5 vs 67.8±26.8 (ng/mL)/(mg/kg), P=0.001] (Figure 1A).

Similarly, carriers of the *ABCB1* 3435 TT genotype also had a significantly higher CsA C_0/D than carriers of the 3435 CT together with CC genotypes [92.0±24.0 vs 68.4±26.5 (ng/mL)/(mg/kg), P=0.002] (Figure 1B).

Although patients with the *ABCB1* 1236TT genotype tended to have higher CsA C_0/D than those with 1236CC or 1236CT genotypes, no significant association was observed between the CsA C_0/D and *ABCB1* C1236T genotype (P=0.097).

When combining the effects of *ABCB1* C1236T, G2677T/A and C3435T, carriers of the 1236TT-2677TT-3435TT haplotype had a considerably higher CsA C_0/D than carriers of other genotypes [97.2±21.8 vs 68.7±26.9 (ng/mL)/(mg/kg), P=0.001] (Figure 1C).

**Association between *NFKB1* genotypes and CsA dose-adjusted trough blood concentrations**

Patients with the *NFKB1* -94 ATTG ins/ins genotype typically had a higher CsA C_0/D than those with the *NFKB1* -94 ATTG del/del genotype [78.5±32.8 vs 61.1±19.4 (ng/mL)/(mg/kg)], but the difference was not statistically significant (P=0.069) (Figure 2A).

**Association between *CYP3A5*, *CYP3A4*, and *NR1I2* genotype and CsA dose-adjusted trough blood concentrations**

Carriers of the *CYP3A5*1/*1 and *1/*3 genotypes were combined as *CYP3A5* expressers, and carriers of the *3/*3 genotype were defined as non-expressers. No significant difference in CsA C_0/D was observed between *CYP3A5* expressers and non-expressers. *CYP3A4*1G SNP was also found not to influence CsA C_0/D. When the effects of *CYP3A5*3 and *CYP3A4*1G were combined, we were still unable to observe any effect of the *CYP3A4-CYP3A5* haplotype on CsA C_0/D.
This study was designed to explore an independent effect of the genes included in this study. Stratification analysis was performed to eliminate any confounding effects of the genes that were included in this study. Among non-carriers of the \( \text{NFKB1} \) -94 ATTG genotype on CsA \( \text{C}_0/\text{D} \) on day 7–18 after transplantation in renal transplant recipients. (B) Influence of the \( \text{NFKB1} \) -94 ATTG genotype on CsA \( \text{C}_0/\text{D} \) on day 7–18 after transplantation in non-carriers of the \( \text{ABCB1} \) 2677 TT and 3435 TT genotypes.

Although numerous SNPs within the \( \text{NRII2} \) gene were included in this study, no association was observed between CsA \( \text{C}_0/\text{D} \) and any of the \( \text{NRII2} \) SNPs (data not shown).

**Stratification analysis**

Stratification analysis was performed to eliminate any confounding effects of the genes that were included in this study. This study was designed to explore an independent effect of \( \text{CYP3A4} \), \( \text{CYP3A5} \), \( \text{NFKB1} \), and \( \text{NRII2} \) genotype on CsA \( \text{C}_0/\text{D} \) after 'standardization' for P-gp activity.

Among non-carriers of the \( \text{ABCB1} \) 2677 TT genotype and 3435 TT genotype, carriers of the \( \text{NFKB1} \) -94 ATTG ins/ins genotype had a significantly higher CsA \( \text{C}_0/\text{D} \) than carriers of the -94 ATTG del/del genotype \([75.9±32.9 \text{ vs } 55.1±15.1 \text{ (ng/mL)}/(\text{mg/kg})] \), \( P=0.026 \) (Figure 2B).

**Discussion**

The current study is a comprehensive study on polymorphisms of drug metabolic enzymes (\( \text{CYP3A4} \) and \( \text{CYP3A5} \)), a transporter (P-gp) and upstream regulators of them (\( \text{PXR} \) and \( \text{NF-κB} \)), to explore the cause of the large inter-individual variation in cyclosporine concentration observed in renal transplant recipients. Moreover, the current study is also directly evaluating the potential effect of NF-κB-related polymorphisms on drug metabolism.

\( \text{ABCB1} \) C1236T, G2677T/A, and C3435T were the most commonly and extensively studied SNPs of \( \text{ABCB1} \), which can form different haplotypes. Carriers of the TT genotype of \( \text{ABCB1} \) C3435T or G2677T/A have been reported to have significantly minimized P-glycoprotein activity compared to wild type activity\([18, 19] \), suggesting a higher CsA \( \text{C}_0/\text{D} \) in carriers of the \( \text{ABCB1} \) 3435 TT and 2677 TT genotypes.

Separate studies on 44 Caucasian liver transplant recipients\([23] \) and 88 Middle Eastern renal transplant recipients\([21] \) up to 1 month after transplantation both found carriers of the \( \text{ABCB1} \) 3435 TT genotype had a higher CsA \( \text{C}_0/\text{D} \) than carriers of 3435 CC or CT genotype. By contrast, in 103 Chinese renal transplant recipients, Qiu et al reported a lower CsA \( \text{C}_0/\text{D} \) in carriers of the \( \text{ABCB1} \) 2677GG wild-type genotype than in carriers of the \( \text{ABCB1} \) 2677TT variant genotype in the first 8 to 30 d after transplantation\([22, 23] \). Consistent with these studies, we found that the \( \text{ABCB1} \) 2677TT and 3435TT genotypes and 1236TT-2677TT-3435TT haplotype were closely correlated with a higher cyclosporine dose-adjusted \( \text{C}_0 \). Moreover, a more obvious influence was found in the 1236TT-2677TT-3435TT haplotype than in each SNP independently; the 1236TT-2677TT-3435TT haplotype contributes more to the variation in CsA concentrations, as determined by multiple linear regression analysis. These findings, which are in agreement with previous observations, suggest that the use of the \( \text{ABCB1} \) haplotype is superior to SNP analysis for predicting concentrations of cyclosporine\([24] \).

As a nuclear factor that takes part in the control of as many as 150 target genes, including many inflammatory genes, NF-κB is a focal point and its related pathways and relationships with many autoimmune diseases and cancers have been widely studied. The majority of studies on NF-κB-related polymorphisms, such as the \( \text{NFKB1} \) -94 ATTG mutation, have been focused on their association with the incidence of tumors and inflammatory diseases\([25] \). Although it has long been observed that inflammatory responses and infections decrease drug metabolism capacity in human, a correlation between NF-κB-related polymorphisms and drug metabolism has never been reported. In a previous in vitro study, Gu et al reported that the structural component of NF-κB, p65, can competitively bind to RXR, which is necessary to form PXR-RXR heterodimers. The competitive binding of p65 to RXR, therefore, disrupts the interaction of PXR-RXR heterodimers with the consensus DNA sequences in the regulatory regions of target genes, thus significantly suppressing gene expression\([21] \). It is possible that NF-κB may have an effect on CsA concentrations by suppressing PXR-mediated regulation of \( \text{CYP3A4}/\text{ABCB1} \). Hence, we speculated that the \( \text{NFKB1} \) polymorphism might result in altered NF-κB expression, leading to reduced \( \text{CYP3A4}/\text{ABCB1} \) expression and increased CsA concentrations.

As reported previously, the del ATTG allele may result in
decreased NFκB1 transcript levels and therefore decreased p50 protein production[12]. Thus, the ins/ins ATTG genotype is speculated to be associated with a higher NF-κB protein content, and consequently lower CYP3A4 expression and ultimately higher CsA concentrations than the levels in carriers of the del/del ATTG genotype. This finding is consistent with our results that carriers of the -94 ATTG ins/ins genotype had a significantly higher CsA C0/D than carriers of the -94 ATTG del/del genotype in non-carriers of the ABCB1 2677 TT and 3435 TT genotypes. These observations suggest that immunoregulation has a notable effect on CsA concentrations. Further study is needed to assess our speculations and reveal the underlying mechanisms.

Although the importance of CYP3A5*3 in tacrolimus concentrations has been fairly obvious, its influence on CsA concentrations is still in dispute. Several researchers[26-28] have observed a significant association between CYP3A5*3 and CsA trough concentrations. However, no association between CYP3A5*3 and CsA concentrations was found in this study, which is in consistent with some previous reports[29-31]. CYP3A4*1G is a CYP3A4 SNP with the highest occurrence in Chinese populations, but a definitive function has not been reported. A series of studies examined the relationship between the CYP3A4*1G polymorphism and drug metabolism but resulted in inconsistent findings[32-34]. In agreement with our observation, CYP3A4*1G was not associated with cyclosporine concentrations in 126 renal recipients[27]; however, Qiu et al[22] and Hu et al[35] found that it was associated with a lower CsA concentration. Differences in study populations, sample size, ethnicities and particularly in the duration after transplantation might be possible confounding factors. During the early stage after transplantation, steroids were used at a high dose, which might have induced CYP3A.

Although they were reported to be functional in previous studies, none of the NR1I2 SNPs were found to be correlated with CsA concentrations in our study.[5,6,8]. However, most of these studies were in vitro, without the consideration of many possible influences caused by other factors in vivo. Another caveat to be taken into account is the induction of PXR by steroids[36] because the recipients in this study, who were at an early stage after transplantation, routinely received a high dose of steroids. Therefore, the impact of NR1I2 SNPs on cyclosporine concentrations at a stable stage after transplantation in patients who received a lower dose of steroids needs to be studied.

In summary, this study reports the potential effect of NF-κB-related polymorphisms on clinical drug metabolism. We also found that the ABCB1 1236TT-2677TT-3435TT haplotype was most significantly correlated with CsA concentrations in Chinese renal transplant recipients. Patients who carry the ABCB1 1236TT-2677TT-3435TT haplotype may be at a greater risk of high CsA concentrations that could lead to hepatotoxicity and nephrotoxicity. NFκB1 polymorphisms were identified as a minor significant factor associated with CsA concentrations in this study, and patients with the NFκB1 ins/ins ATTG genotype tended to have higher CsA concentrations. We also propose that pre-transplant genotyping of the ABCB1 C1236T, G2677T/A, C3435T, and NFκB1 ins/ins ATTG genotypes may be used as an index for CsA dosing in clinical practice and that the initial CsA dose for carriers of the ABCB1 1236TT-2677TT-3435TT haplotype and NFκB1 -94 ins/ins ATTG genotype be lower to prevent possible toxicities during the early stage of transplantation.

Acknowledgements
We appreciate the financial support provided by a National Science and Technology Major Project in Science and Technology grant from the Science and Technology Ministry of China (Grant No 2012ZX09306001-004), National Natural Science Foundations of China (No 81102515, 81072708, and 81173131) and Medical Research Foundation of Guangdong Province (No B2011067).

Author contribution
Yu ZHANG, Jia-li LI, Min HUANG, and Chang-xi WANG designed the research. Yu ZHANG, Jia-li LI, Xue-ding WANG, Qian FU, and Long-shan LIU performed the research. Yu ZHANG, Jia-li LI, and Wen-ying SHU contributed new reagents and analytic tools. Yu ZHANG and Zhuo-jia CHEN analyzed the data. Yu ZHANG and Zhuo-jia CHEN wrote the paper.

References
1 Ptachinski RJ, Venkataramanan R, Burckart GJ. Clinical pharmacokinetics of cyclosporin. Clin Pharmacokinet 1986; 11: 107–32.
2 Kahan BD, Keown P, Levy GA, Johnston A. Therapeutic drug monitoring of immunosuppressant drugs in clinical practice. Clin Ther 2002; 24: 330–50.
3 Staatz CE, Goodman LK, Tett SE. Effect of CYP3A and ABCB1 single nucleotide polymorphisms on the pharmacokinetics and pharmacodynamics of calcineurin inhibitors: Part I. Clin Pharmacokinet 2010; 49: 207–21.
4 Wang H, LeCluyse EL. Role of orphan nuclear receptors in the regulation of drug-metabolising enzymes. Clin Pharmacokinet 2003; 42: 1331–57.
5 Zhang J, Kuehl P, Green ED, Touchman JW, Watkins PB, Daly A, et al. The human pregnancy X receptor: genomic structure and identification and functional characterization of natural allelic variants. Pharmacogenetics 2001; 11: 555–72.
6 Lamba J, Lamba V, Strom S, Venkataramanan R, Schuetz E. Novel single nucleotide polymorphisms in the promoter and intron 1 of human pregnancy X receptor/FR112 and their association with CYP3A4 expression. Drug Metab Dispos 2006; 38: 169–81.
7 Wang XD, Deng XY, Chen J, Li JL, Chen X, Zhao LZ, et al. Single nucleotide polymorphisms of the pregnancy X receptor gene in Han Chinese and a comparison with other ethnic populations. Pharmacology 2008; 81: 350–4.
8 Wang XD, Li JL, Su QB, Deng XY, Lu Y, Chen J, et al. A pharmacogenetic study of pregnancy X receptor (NR12) in Han Chinese. Curr Drug Metab 2007; 8: 778–86.
9 Morgan ET. Regulation of cytochromes P450 during inflammation and infection. Drug Metab Rev 1997; 29: 1129–88.
10 Renton KW. Cytochrome P450 regulation and drug biotransformation during inflammation and infection. Curr Drug Metab 2004; 5:
11 Gu X. Role of NF-κB in regulation of PXR-mediated gene expression: A mechanism for the suppression of cytochrome P-450 3A4 by proinflammatory agents. J Biol Chem 2006; 281: 17882–9.

12 Karban AS, Okazaki T, Panhuysen CI, Gallegos T, Potter JJ, Bailey-Wilson JE, et al. Functional annotation of a novel NFKB1 promoter polymorphism that increases risk for ulcerative colitis. Hum Mol Genet 2004; 13: 35–45.

13 Sabate I, Ginard M, Gonzalez JM, Baro E, Acebes G, Cuadros J, et al. Evaluation of the AxSYM monoclonal cyclosporin assay and comparison with radioimmunoassay. Ther Drug Monit 2000; 22: 474–80.

14 Loparev VN, Cartas MA, Monken CE, Velpandi A, Srinivasan A. Role of NF-κB in regulation of PXR-mediated gene expression: An efficient and simple method of DNA extraction from whole blood and cell lines to identify infectious agents. J Virol Methods 1991; 34: 105–12.

15 Wang Y, Wang C, Li J, Wang X, Zhu G, Chen X, et al. Effect of genetic polymorphisms of CYP3A5 and MDR1 on cyclosporine concentration during the early stage after renal transplantation in Chinese patients co-treated with diltiazem. Eur J Clin Pharmacol 2009; 65: 239–47.

16 Gao Y, Zhang LR, Fu Q. CYP3A4*1G polymorphism is associated with lipid-lowering efficacy of atorvastatin but not of simvastatin. Eur J Clin Pharmacol 2008; 64: 877–82.

17 Senol Tuncay S, Okay P, Bardakci F. Identification of NF-κB1 and NF-κB1α polymorphisms using PCR-RFLP assay in a Turkish population. Biochem Genet 2010; 48: 104–12.

18 Kimchi-Sarfaty C, Oh JM, Kim IW, Sauna ZE, Calcagno AM, Ambudkar SV, et al. A “silent” polymorphism in the MDR1 gene changes substrate specificity. Science 2007; 315: 525–8.

19 Wang D, Johnson AD, Papp AC, Kroetz DL, Sadee W. Multidrug resistance polypeptide 1 (MDR1, ABCB1) variant 3435C>T affects mRNA stability. Pharmacogenet Genomics 2005; 15: 693–704.

20 Bonhomme-Faivre L, Devocelle A, Saliba F, Chatlled S, Maccario J, Farinotti R, et al. MDR-1 C3435T polymorphism influences cyclosporine a dose requirement in liver-transplant recipients. Transplantation 2004; 78: 21–5.

21 Azarpira N AM, Behzad-Behbahanie A, Geramizadeh B, Behzadi S, Malekhusseinie SA, Raisjalahi GH, et al. Association between cyclosporine concentration and genetic polymorphisms of CYP3A5 and MDR1 during the early stage after renal transplantation. Exp Clin Transplant 2006; 4: 416–9.

22 Qiu XY, Jiao Z, Zhang M, Zhong LJ, Liang HQ, Ma CL, et al. Association of MDR1, CYP3A4*18B, and CYP3A5*3 polymorphisms with cyclosporine pharmacokinetics in Chinese kidney transplant recipients. Eur J Clin Pharmacol 2008; 64: 1069–84.

23 Turolo S, Tirelli AS, Ferraresso M, Ghio L, Belingheri M, Groppali E, et al. Frequencies and roles of CYP3A5, CYP3A4, and ABCB1 single nucleotide polymorphisms in Italian teenagers after kidney transplantation. Pharmacol Rep 2010; 62: 1159–69.

24 Chowbay B, Cumaraswamy S, Cheung YB, Zhou Q, Lee EJ. Genetic polymorphisms in MDR1 and CYP3A4 genes in Asians and the influence of MDR1 haplotypes on cyclosporin disposition in heart transplant recipients. Pharmacogenetics 2003; 13: 89–95.